Purchased mezagitamab royalty and milestone rights held by BioInvent International and will secure royalty economic interests in two early-stage partnered assets through XOMA Royalty’s recently ...

XOMA Royalty Corporation (XOMA) on Wednesday reported second-quarter net income of $9.2 million. On a per-share basis, the Emeryville, California-based company said it had profit of 44 cents.

Key Points Revenue (GAAP) beat estimates by 39.5% in Q2 2025, rising to $13.1 million on substantial milestone receipts. Recurring royalty income remained modest, with only $2.6 million from ...

XOMA Royalty (XOMA) came out with quarterly earnings of $0.48 per share, beating the Zacks Consensus Estimate of a loss of $0.12 per share. This compares to a loss of $0.28 per share a year ago. These ...

Reports Q2 revenue $13.129M, consensus $9.39M. “We continue to add to our diversified portfolio of both early- and late-stage assets through ...

Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations ...